6533b860fe1ef96bd12c3235
RESEARCH PRODUCT
Severe eosinophilic asthma: a roadmap to consensus
R BuhlM HumbertL BjermerP ChanezLg HeaneyI PavordS QuirceJc VirchowS HolgateExpert Group Of The European Consensus Meeting For Severe Eosinophilic Asthmasubject
Pulmonary and Respiratory Medicinemedicine.medical_specialtyConsensusEosinophilic asthmamacromolecular substancesSeverity of Illness IndexBiological Factors03 medical and health sciences0302 clinical medicineimmune system diseasesEosinophilicmedicineHumans030212 general & internal medicinePulmonary EosinophiliaIntensive care medicineSocieties MedicalTask forcebusiness.industryDisease ManagementAsthmarespiratory tract diseasesEurope030228 respiratory systemImmunologybusinessdescription
Asthma is widely accepted as a complex heterogeneous condition with diverse pathophysiological mechanisms, clinical presentations, comorbidities, physiological characteristics, pathology and outcomes that is typically best managed by a multidisciplinary team [1–4]. Severe asthma is recognised as a major unmet need with a high personal and social impact, as well as a high burden on healthcare resources [4]. As a consequence of advances in the development of precision medicines for patients with severe asthma, the need to identify asthma subtypes by phenotype based on clinical, functional or inflammatory parameters is becoming a mandatory part of management [4–6]. Severe eosinophilic asthma (SEA), also referred to as severe asthma with eosinophilia, is yet to be clearly defined and warrants further discussion. A task force has identified key consensus issues for defining, diagnosing and treating severe eosinophilic asthma.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-05-01 | European Respiratory Journal |